Interstitial lung diseases (ILDs) represent a diverse group of over 200 lung disorders characterized by inflammation and fibrosis of the alveolar walls. This article provides a comprehensive overview of the causes, symptoms, and treatment strategies for ILDs.
ILDs may be idiopathic or associated with various factors such as occupational and environmental exposures, systemic diseases, and certain medications. Smoking, age, and a family history of ILDs are other significant risk factors.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Other symptoms may include fatigue, weight loss, and clubbing. The physical examination may reveal inspiratory crackles and signs of pulmonary hypertension in advanced stages.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs, providing detailed images of the lung parenchyma. Pulmonary function tests reveal a restrictive pattern with reduced diffusing capacity for carbon monoxide. In certain cases, a lung biopsy may be necessary to establish a definitive diagnosis.
Management of ILDs involves addressing the underlying cause, if identified, and slowing disease progression. Pharmacologic therapy includes corticosteroids and immunosuppressive agents. Antifibrotic drugs such as pirfenidone and nintedanib have shown efficacy in idiopathic pulmonary fibrosis. Lung transplantation may be considered in selected patients with advanced disease.
Given the chronic and progressive nature of ILDs, palliative care focusing on symptom management and improving quality of life is essential. The prognosis varies widely depending on the specific type of ILD, ranging from relatively benign to rapidly progressive and fatal.
Interstitial lung diseases are complex disorders requiring a comprehensive approach to diagnosis and management. Understanding the diverse etiologies, recognizing the clinical manifestations, and being familiar with the current treatment strategies are crucial for optimal patient care.
1.
Aspirin Fails to Boost Survival in Colorectal Cancer Trial
2.
Do Anatomy Atlases Reflect Social Inequalities?
3.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
4.
Some triple negative breast cancers might be avoided by longer breastfeeding
5.
Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Metabolic Competition Within the Tumor Ecosystem: Mechanisms, Clinical Relevance, and Therapeutic Advances
3.
Ferroptosis-Modulating Nanocarriers for Solid Tumor Therapy
4.
Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients
5.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Excellence in Hematology
2.
Navigating the Complexities of Ph Negative ALL - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Understanding the causes of anemia in adults beyond nutritional deficiencies
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation